 Christopher Porter
Concepts (329)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Germ-Line Mutation | 7 | 2022 | 130 | 2.290 |
Why?
| | Proto-Oncogene Proteins c-ets | 5 | 2022 | 51 | 2.230 |
Why?
| | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 8 | 2023 | 256 | 2.050 |
Why?
| | Leukemia | 5 | 2023 | 209 | 1.970 |
Why?
| | Pyrimidines | 6 | 2017 | 376 | 1.700 |
Why?
| | Leukemia, Myeloid, Acute | 9 | 2023 | 534 | 1.700 |
Why?
| | Interleukin-12 | 3 | 2022 | 110 | 1.580 |
Why?
| | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2023 | 64 | 1.420 |
Why?
| | Pyrazoles | 4 | 2017 | 362 | 1.340 |
Why?
| | Repressor Proteins | 5 | 2022 | 366 | 1.330 |
Why?
| | Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 3 | 2023 | 16 | 1.310 |
Why?
| | Thrombocytopenia | 4 | 2020 | 177 | 1.270 |
Why?
| | Neoplastic Syndromes, Hereditary | 2 | 2019 | 30 | 1.190 |
Why?
| | Genetic Testing | 3 | 2021 | 381 | 1.180 |
Why?
| | Cell Cycle Proteins | 4 | 2017 | 551 | 1.160 |
Why?
| | Protein-Tyrosine Kinases | 3 | 2017 | 395 | 1.120 |
Why?
| | Nuclear Proteins | 3 | 2017 | 591 | 1.040 |
Why?
| | Burkitt Lymphoma | 2 | 2023 | 52 | 1.030 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 3 | 2017 | 1355 | 0.900 |
Why?
| | Hematopoietic Stem Cells | 6 | 2021 | 343 | 0.860 |
Why?
| | Genetic Predisposition to Disease | 9 | 2021 | 2086 | 0.780 |
Why?
| | Hematologic Neoplasms | 1 | 2023 | 137 | 0.770 |
Why?
| | Neoplasms | 6 | 2023 | 2097 | 0.740 |
Why?
| | Hypoxanthine Phosphoribosyltransferase | 2 | 2013 | 24 | 0.740 |
Why?
| | RNA, Small Interfering | 6 | 2018 | 535 | 0.700 |
Why?
| | Cytarabine | 3 | 2017 | 51 | 0.660 |
Why?
| | Cell Line, Tumor | 13 | 2022 | 2710 | 0.650 |
Why?
| | Gene Knockdown Techniques | 4 | 2019 | 299 | 0.650 |
Why?
| | Pyrimidinones | 5 | 2017 | 88 | 0.630 |
Why?
| | Calcineurin | 1 | 2019 | 89 | 0.620 |
Why?
| | Antimetabolites, Antineoplastic | 3 | 2013 | 81 | 0.610 |
Why?
| | Mice | 20 | 2023 | 14869 | 0.610 |
Why?
| | Tumor Microenvironment | 5 | 2023 | 430 | 0.610 |
Why?
| | Hematologic Diseases | 2 | 2015 | 55 | 0.600 |
Why?
| | Apoptosis | 9 | 2022 | 2363 | 0.600 |
Why?
| | Neoplasm Proteins | 3 | 2021 | 385 | 0.590 |
Why?
| | Cyclin-Dependent Kinase 2 | 1 | 2017 | 32 | 0.580 |
Why?
| | CDC2 Protein Kinase | 1 | 2017 | 25 | 0.580 |
Why?
| | Recombinational DNA Repair | 1 | 2017 | 9 | 0.580 |
Why?
| | Antineoplastic Agents | 7 | 2022 | 1879 | 0.570 |
Why?
| | Li-Fraumeni Syndrome | 1 | 2017 | 11 | 0.570 |
Why?
| | Phthalazines | 1 | 2017 | 38 | 0.560 |
Why?
| | Thioguanine | 3 | 2013 | 19 | 0.550 |
Why?
| | Myelodysplastic Syndromes | 1 | 2017 | 119 | 0.510 |
Why?
| | Piperazines | 2 | 2017 | 309 | 0.500 |
Why?
| | Tumor Suppressor Protein p53 | 5 | 2017 | 445 | 0.500 |
Why?
| | Fusion Proteins, bcr-abl | 2 | 2014 | 61 | 0.470 |
Why?
| | Cytokines | 4 | 2023 | 1841 | 0.460 |
Why?
| | Calcineurin Inhibitors | 1 | 2014 | 58 | 0.460 |
Why?
| | DNA Repair | 1 | 2015 | 184 | 0.450 |
Why?
| | Humans | 51 | 2023 | 114686 | 0.440 |
Why?
| | Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2014 | 95 | 0.440 |
Why?
| | Animals | 20 | 2023 | 31706 | 0.430 |
Why?
| | Xenograft Model Antitumor Assays | 7 | 2018 | 698 | 0.420 |
Why?
| | Bone Marrow | 3 | 2022 | 243 | 0.410 |
Why?
| | Transduction, Genetic | 1 | 2013 | 113 | 0.410 |
Why?
| | Drug Synergism | 4 | 2015 | 316 | 0.410 |
Why?
| | Drug Resistance | 2 | 2013 | 158 | 0.390 |
Why?
| | Drug Resistance, Neoplasm | 4 | 2017 | 636 | 0.390 |
Why?
| | Child | 17 | 2023 | 18414 | 0.370 |
Why?
| | Lymphoproliferative Disorders | 2 | 2008 | 46 | 0.370 |
Why?
| | Leukemia, Experimental | 1 | 2011 | 27 | 0.370 |
Why?
| | Myeloproliferative Disorders | 1 | 2011 | 26 | 0.360 |
Why?
| | Genomics | 3 | 2022 | 635 | 0.350 |
Why?
| | Charcot-Marie-Tooth Disease | 1 | 2009 | 19 | 0.320 |
Why?
| | Vincristine | 1 | 2009 | 98 | 0.310 |
Why?
| | Influenza Vaccines | 2 | 2004 | 497 | 0.310 |
Why?
| | Peripheral Nervous System Diseases | 1 | 2009 | 120 | 0.300 |
Why?
| | Triazoles | 1 | 2009 | 131 | 0.290 |
Why?
| | Flow Cytometry | 4 | 2019 | 1083 | 0.290 |
Why?
| | Purines | 1 | 2008 | 159 | 0.280 |
Why?
| | Cell Separation | 1 | 2008 | 291 | 0.280 |
Why?
| | CD8-Positive T-Lymphocytes | 2 | 2023 | 687 | 0.270 |
Why?
| | DNA Damage | 3 | 2017 | 351 | 0.260 |
Why?
| | Organ Transplantation | 1 | 2008 | 159 | 0.260 |
Why?
| | Medical Oncology | 3 | 2023 | 229 | 0.260 |
Why?
| | DNA-Binding Proteins | 2 | 2012 | 1314 | 0.250 |
Why?
| | Biomarkers, Tumor | 1 | 2012 | 1040 | 0.250 |
Why?
| | Female | 20 | 2021 | 59507 | 0.240 |
Why?
| | Hematopoietic Stem Cell Transplantation | 3 | 2019 | 520 | 0.230 |
Why?
| | Influenza B virus | 1 | 2004 | 34 | 0.220 |
Why?
| | Syndrome | 2 | 2023 | 333 | 0.220 |
Why?
| | Sialic Acid Binding Immunoglobulin-like Lectins | 1 | 2023 | 5 | 0.220 |
Why?
| | Interferon-gamma | 2 | 2017 | 719 | 0.210 |
Why?
| | Immunoglobulins | 1 | 2023 | 143 | 0.210 |
Why?
| | Mice, Inbred C57BL | 4 | 2021 | 4694 | 0.210 |
Why?
| | Triple Negative Breast Neoplasms | 2 | 2016 | 157 | 0.210 |
Why?
| | Brain Diseases, Metabolic, Inborn | 1 | 2022 | 1 | 0.210 |
Why?
| | Thrombopoiesis | 1 | 2022 | 6 | 0.210 |
Why?
| | Germ Cells | 1 | 2022 | 57 | 0.200 |
Why?
| | Adaptive Immunity | 1 | 2023 | 155 | 0.200 |
Why?
| | Galectins | 1 | 2022 | 22 | 0.200 |
Why?
| | Mutation | 4 | 2022 | 3346 | 0.200 |
Why?
| | Urogenital Abnormalities | 1 | 2022 | 48 | 0.190 |
Why?
| | Thrombopoietin | 1 | 2021 | 4 | 0.190 |
Why?
| | Immunization | 1 | 2004 | 397 | 0.190 |
Why?
| | Metabolic Diseases | 1 | 2022 | 98 | 0.190 |
Why?
| | Mobile Applications | 1 | 2023 | 141 | 0.190 |
Why?
| | Genes, p53 | 2 | 2012 | 61 | 0.180 |
Why?
| | Nuclear Receptor Co-Repressor 2 | 1 | 2020 | 14 | 0.180 |
Why?
| | Bone Marrow Diseases | 1 | 2020 | 18 | 0.180 |
Why?
| | Interferon Regulatory Factors | 1 | 2020 | 29 | 0.180 |
Why?
| | Cell- and Tissue-Based Therapy | 1 | 2021 | 56 | 0.180 |
Why?
| | Phenotype | 4 | 2023 | 2796 | 0.170 |
Why?
| | Antibodies, Bispecific | 1 | 2020 | 32 | 0.170 |
Why?
| | Core Binding Factor Alpha 2 Subunit | 1 | 2019 | 31 | 0.170 |
Why?
| | Leukemia, Myeloid | 1 | 2019 | 40 | 0.170 |
Why?
| | Cell Line | 5 | 2021 | 2637 | 0.170 |
Why?
| | Cardiomyopathy, Dilated | 1 | 2022 | 348 | 0.160 |
Why?
| | Dendritic Cells | 1 | 2022 | 435 | 0.160 |
Why?
| | Membrane Proteins | 2 | 2023 | 1019 | 0.160 |
Why?
| | Tumor Escape | 1 | 2019 | 35 | 0.160 |
Why?
| | Up-Regulation | 3 | 2018 | 808 | 0.160 |
Why?
| | Cardiomyopathies | 1 | 2022 | 298 | 0.160 |
Why?
| | Histone Deacetylases | 1 | 2020 | 195 | 0.160 |
Why?
| | PAX2 Transcription Factor | 1 | 2018 | 6 | 0.160 |
Why?
| | Osmoregulation | 1 | 2018 | 3 | 0.160 |
Why?
| | NADPH Oxidases | 2 | 2017 | 120 | 0.160 |
Why?
| | PAX5 Transcription Factor | 1 | 2018 | 12 | 0.160 |
Why?
| | Disease Progression | 2 | 2019 | 2380 | 0.160 |
Why?
| | Disease Management | 2 | 2019 | 560 | 0.160 |
Why?
| | Lesch-Nyhan Syndrome | 1 | 2018 | 3 | 0.160 |
Why?
| | Anemia, Macrocytic | 1 | 2018 | 4 | 0.160 |
Why?
| | Interferon-alpha | 1 | 2019 | 186 | 0.150 |
Why?
| | Protein Kinase Inhibitors | 2 | 2014 | 785 | 0.150 |
Why?
| | Infant | 5 | 2021 | 7963 | 0.140 |
Why?
| | Hepatoblastoma | 1 | 2017 | 27 | 0.140 |
Why?
| | Anion Transport Proteins | 1 | 2017 | 8 | 0.140 |
Why?
| | TNF-Related Apoptosis-Inducing Ligand | 1 | 2017 | 40 | 0.140 |
Why?
| | Receptors, TNF-Related Apoptosis-Inducing Ligand | 1 | 2017 | 26 | 0.140 |
Why?
| | Family | 1 | 2021 | 589 | 0.140 |
Why?
| | Interleukin-1 | 1 | 2021 | 966 | 0.130 |
Why?
| | RNA | 1 | 2022 | 809 | 0.130 |
Why?
| | Wilms Tumor | 1 | 2017 | 68 | 0.130 |
Why?
| | T-Lymphocytes | 2 | 2021 | 1737 | 0.130 |
Why?
| | Genotype | 1 | 2021 | 1760 | 0.130 |
Why?
| | Calcitriol | 1 | 2016 | 53 | 0.130 |
Why?
| | Prednisolone | 1 | 2015 | 75 | 0.120 |
Why?
| | Lymphocyte Activation | 1 | 2019 | 1037 | 0.120 |
Why?
| | Pediatrics | 1 | 2003 | 980 | 0.120 |
Why?
| | Telemedicine | 1 | 2023 | 662 | 0.120 |
Why?
| | Protein Tyrosine Phosphatases | 1 | 2016 | 147 | 0.120 |
Why?
| | Hemorrhage | 1 | 2019 | 620 | 0.120 |
Why?
| | Cells, Cultured | 4 | 2011 | 3886 | 0.120 |
Why?
| | Male | 13 | 2021 | 55596 | 0.120 |
Why?
| | Down Syndrome | 1 | 2019 | 335 | 0.120 |
Why?
| | Genetic Variation | 1 | 2019 | 870 | 0.120 |
Why?
| | Practice Patterns, Physicians' | 1 | 2003 | 1177 | 0.120 |
Why?
| | Pyridones | 1 | 2015 | 123 | 0.120 |
Why?
| | Dasatinib | 1 | 2014 | 46 | 0.110 |
Why?
| | Oligonucleotide Array Sequence Analysis | 2 | 2017 | 740 | 0.110 |
Why?
| | S Phase | 2 | 2012 | 69 | 0.110 |
Why?
| | Thiazoles | 1 | 2014 | 110 | 0.110 |
Why?
| | MAP Kinase Signaling System | 1 | 2015 | 276 | 0.110 |
Why?
| | Cyclosporine | 1 | 2014 | 161 | 0.110 |
Why?
| | Blotting, Western | 2 | 2017 | 1147 | 0.110 |
Why?
| | Early Detection of Cancer | 1 | 2017 | 328 | 0.110 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2019 | 959 | 0.110 |
Why?
| | Cell Cycle Checkpoints | 1 | 2013 | 84 | 0.110 |
Why?
| | Cell Proliferation | 2 | 2017 | 2187 | 0.110 |
Why?
| | Membrane Glycoproteins | 1 | 2015 | 430 | 0.110 |
Why?
| | Antigens, CD34 | 1 | 2013 | 89 | 0.100 |
Why?
| | Vitamin D | 1 | 2016 | 341 | 0.100 |
Why?
| | Umbilical Cord | 1 | 2013 | 80 | 0.100 |
Why?
| | STAT3 Transcription Factor | 1 | 2014 | 173 | 0.100 |
Why?
| | Tankyrases | 1 | 2012 | 12 | 0.100 |
Why?
| | Cell Differentiation | 2 | 2018 | 1701 | 0.100 |
Why?
| | Child, Preschool | 5 | 2018 | 9116 | 0.100 |
Why?
| | Neutrophils | 1 | 2017 | 1176 | 0.100 |
Why?
| | Immunity, Innate | 1 | 2017 | 720 | 0.100 |
Why?
| | Drug Discovery | 1 | 2013 | 123 | 0.100 |
Why?
| | Inflammation | 1 | 2022 | 2480 | 0.100 |
Why?
| | Myeloid Cells | 1 | 2013 | 126 | 0.100 |
Why?
| | Proto-Oncogene Proteins c-met | 1 | 2012 | 67 | 0.100 |
Why?
| | Autophagy | 1 | 2014 | 235 | 0.100 |
Why?
| | Kidney | 1 | 2018 | 1188 | 0.100 |
Why?
| | Wnt Proteins | 1 | 2012 | 134 | 0.090 |
Why?
| | Lymphocytes | 1 | 2013 | 330 | 0.090 |
Why?
| | Aging | 1 | 2021 | 1618 | 0.090 |
Why?
| | Gene Knock-In Techniques | 1 | 2011 | 46 | 0.090 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2012 | 313 | 0.090 |
Why?
| | Adult | 8 | 2023 | 30550 | 0.090 |
Why?
| | Infant, Newborn | 1 | 2021 | 5047 | 0.090 |
Why?
| | Tumor Cells, Cultured | 1 | 2012 | 849 | 0.090 |
Why?
| | Tumor Suppressor Proteins | 1 | 2012 | 282 | 0.090 |
Why?
| | Genome, Human | 1 | 2012 | 347 | 0.080 |
Why?
| | Obesity | 1 | 2022 | 2508 | 0.080 |
Why?
| | Immunologic Factors | 2 | 2023 | 220 | 0.080 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2012 | 923 | 0.080 |
Why?
| | Cell Cycle | 2 | 2012 | 542 | 0.080 |
Why?
| | Cyclophilin A | 1 | 2009 | 24 | 0.080 |
Why?
| | Basigin | 1 | 2009 | 25 | 0.080 |
Why?
| | Pregnancy | 1 | 2021 | 5518 | 0.080 |
Why?
| | Oncogene Proteins, Fusion | 1 | 2011 | 179 | 0.080 |
Why?
| | ErbB Receptors | 1 | 2012 | 554 | 0.080 |
Why?
| | Voriconazole | 1 | 2009 | 24 | 0.080 |
Why?
| | Proto-Oncogene Proteins c-bcl-6 | 1 | 2008 | 6 | 0.080 |
Why?
| | Clinical Trials as Topic | 1 | 2013 | 932 | 0.080 |
Why?
| | Lentivirus | 1 | 2008 | 44 | 0.080 |
Why?
| | Protein Folding | 1 | 2009 | 239 | 0.070 |
Why?
| | Genetic Vectors | 1 | 2008 | 289 | 0.070 |
Why?
| | Epstein-Barr Virus Infections | 1 | 2007 | 72 | 0.060 |
Why?
| | Genetic Association Studies | 2 | 2019 | 339 | 0.060 |
Why?
| | Gene Expression Profiling | 1 | 2012 | 1518 | 0.060 |
Why?
| | Cohort Studies | 2 | 2020 | 4895 | 0.060 |
Why?
| | Hodgkin Disease | 1 | 2007 | 121 | 0.060 |
Why?
| | HEK293 Cells | 2 | 2018 | 591 | 0.060 |
Why?
| | RNA, Messenger | 1 | 2012 | 2553 | 0.060 |
Why?
| | B-Lymphocytes | 2 | 2020 | 766 | 0.060 |
Why?
| | Survival Rate | 1 | 2008 | 1644 | 0.060 |
Why?
| | DNA Replication | 1 | 2005 | 202 | 0.060 |
Why?
| | Hemagglutination Inhibition Tests | 1 | 2004 | 37 | 0.060 |
Why?
| | Serologic Tests | 1 | 2004 | 49 | 0.060 |
Why?
| | Mice, Inbred BALB C | 2 | 2021 | 1144 | 0.060 |
Why?
| | Cell Transformation, Neoplastic | 1 | 2005 | 308 | 0.050 |
Why?
| | Adolescent | 4 | 2019 | 17844 | 0.050 |
Why?
| | Remission Induction | 1 | 2023 | 233 | 0.050 |
Why?
| | Antigens, Viral | 1 | 2004 | 176 | 0.050 |
Why?
| | Middle Aged | 3 | 2019 | 26737 | 0.050 |
Why?
| | Antigens, Neoplasm | 1 | 2023 | 222 | 0.050 |
Why?
| | Single-Cell Analysis | 1 | 2023 | 188 | 0.050 |
Why?
| | Receptors, Thrombopoietin | 1 | 2021 | 5 | 0.050 |
Why?
| | Mitochondrial Proteins | 1 | 2023 | 219 | 0.050 |
Why?
| | Rare Diseases | 1 | 2022 | 89 | 0.050 |
Why?
| | Receptors, Cytokine | 1 | 2021 | 33 | 0.050 |
Why?
| | Disease Models, Animal | 1 | 2011 | 3535 | 0.050 |
Why?
| | Mice, Nude | 2 | 2014 | 630 | 0.050 |
Why?
| | Disease Susceptibility | 1 | 2023 | 316 | 0.050 |
Why?
| | Sequence Analysis, RNA | 1 | 2023 | 385 | 0.050 |
Why?
| | Acute Disease | 1 | 2023 | 911 | 0.050 |
Why?
| | Prognosis | 1 | 2008 | 3329 | 0.040 |
Why?
| | Recurrence | 1 | 2023 | 935 | 0.040 |
Why?
| | Megakaryocytes | 1 | 2020 | 30 | 0.040 |
Why?
| | Treatment Outcome | 1 | 2014 | 9088 | 0.040 |
Why?
| | Antibodies, Viral | 1 | 2004 | 520 | 0.040 |
Why?
| | CD3 Complex | 1 | 2020 | 92 | 0.040 |
Why?
| | Antigens, CD19 | 1 | 2020 | 91 | 0.040 |
Why?
| | Liver Transplantation | 1 | 2007 | 707 | 0.040 |
Why?
| | Lung Neoplasms | 1 | 2012 | 2177 | 0.040 |
Why?
| | Carrier Proteins | 1 | 2023 | 695 | 0.040 |
Why?
| | Ligands | 1 | 2021 | 562 | 0.040 |
Why?
| | Penetrance | 1 | 2019 | 27 | 0.040 |
Why?
| | Polymers | 1 | 2023 | 448 | 0.040 |
Why?
| | Protein Transport | 1 | 2020 | 395 | 0.040 |
Why?
| | DNA | 1 | 2005 | 1352 | 0.040 |
Why?
| | Hypertonic Solutions | 1 | 2018 | 7 | 0.040 |
Why?
| | Polyethylene Glycols | 1 | 2023 | 561 | 0.040 |
Why?
| | Coculture Techniques | 1 | 2018 | 201 | 0.040 |
Why?
| | Primary Cell Culture | 1 | 2018 | 149 | 0.040 |
Why?
| | Proto-Oncogene Proteins | 1 | 2021 | 608 | 0.040 |
Why?
| | Muramidase | 1 | 2017 | 72 | 0.040 |
Why?
| | Chemotaxis, Leukocyte | 1 | 2017 | 130 | 0.040 |
Why?
| | Peroxidase | 1 | 2017 | 163 | 0.040 |
Why?
| | Clinical Decision-Making | 1 | 2019 | 268 | 0.030 |
Why?
| | Case-Control Studies | 1 | 2004 | 3003 | 0.030 |
Why?
| | Immunotherapy | 1 | 2020 | 474 | 0.030 |
Why?
| | Europe | 1 | 2017 | 334 | 0.030 |
Why?
| | Mice, Transgenic | 1 | 2021 | 1949 | 0.030 |
Why?
| | MAP Kinase Kinase 4 | 1 | 2015 | 23 | 0.030 |
Why?
| | Vaccination | 1 | 2004 | 1204 | 0.030 |
Why?
| | Phagocytosis | 1 | 2017 | 350 | 0.030 |
Why?
| | MAP Kinase Kinase 2 | 1 | 2015 | 27 | 0.030 |
Why?
| | Oncogenes | 1 | 2016 | 103 | 0.030 |
Why?
| | NADPH Oxidase 2 | 1 | 2015 | 42 | 0.030 |
Why?
| | Drug Screening Assays, Antitumor | 1 | 2016 | 180 | 0.030 |
Why?
| | Erythrocytes, Abnormal | 1 | 2015 | 12 | 0.030 |
Why?
| | Autophagy-Related Protein 7 | 1 | 2014 | 5 | 0.030 |
Why?
| | Beclin-1 | 1 | 2014 | 9 | 0.030 |
Why?
| | United States | 2 | 2017 | 12183 | 0.030 |
Why?
| | Ubiquitin-Activating Enzymes | 1 | 2014 | 13 | 0.030 |
Why?
| | Exome | 1 | 2015 | 200 | 0.030 |
Why?
| | Pedigree | 1 | 2015 | 460 | 0.030 |
Why?
| | DNA Mutational Analysis | 1 | 2015 | 372 | 0.030 |
Why?
| | Chloroquine | 1 | 2014 | 52 | 0.030 |
Why?
| | Gene Expression Regulation | 2 | 2017 | 2320 | 0.030 |
Why?
| | Cell Survival | 1 | 2017 | 1021 | 0.030 |
Why?
| | Young Adult | 2 | 2019 | 10469 | 0.030 |
Why?
| | Apoptosis Regulatory Proteins | 1 | 2014 | 171 | 0.030 |
Why?
| | Mutation, Missense | 1 | 2015 | 293 | 0.030 |
Why?
| | Tumor Burden | 1 | 2014 | 259 | 0.030 |
Why?
| | Doxorubicin | 1 | 2014 | 285 | 0.030 |
Why?
| | Genes, Synthetic | 1 | 2012 | 14 | 0.030 |
Why?
| | Genes, Lethal | 1 | 2012 | 26 | 0.030 |
Why?
| | Adenocarcinoma, Bronchiolo-Alveolar | 1 | 2012 | 19 | 0.030 |
Why?
| | Signal Transduction | 2 | 2017 | 4513 | 0.030 |
Why?
| | Reproducibility of Results | 1 | 2019 | 2764 | 0.030 |
Why?
| | Ataxia Telangiectasia Mutated Proteins | 1 | 2012 | 63 | 0.020 |
Why?
| | Age Factors | 1 | 2019 | 2894 | 0.020 |
Why?
| | RNA Interference | 1 | 2014 | 433 | 0.020 |
Why?
| | Mice, Knockout | 2 | 2010 | 2570 | 0.020 |
Why?
| | Longitudinal Studies | 1 | 2018 | 2387 | 0.020 |
Why?
| | Protein Processing, Post-Translational | 1 | 2014 | 399 | 0.020 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2017 | 1141 | 0.020 |
Why?
| | Surveys and Questionnaires | 1 | 2003 | 4623 | 0.020 |
Why?
| | Imidazoles | 1 | 2012 | 208 | 0.020 |
Why?
| | Prospective Studies | 1 | 2022 | 6220 | 0.020 |
Why?
| | Quinazolines | 1 | 2012 | 240 | 0.020 |
Why?
| | Radiation, Ionizing | 1 | 2010 | 72 | 0.020 |
Why?
| | Phosphorylation | 1 | 2014 | 1569 | 0.020 |
Why?
| | Syndecan-1 | 1 | 2009 | 27 | 0.020 |
Why?
| | Genome-Wide Association Study | 1 | 2015 | 1177 | 0.020 |
Why?
| | Lymphoma | 1 | 2010 | 177 | 0.020 |
Why?
| | Bone Marrow Transplantation | 1 | 2010 | 239 | 0.020 |
Why?
| | Catalysis | 1 | 2009 | 289 | 0.020 |
Why?
| | Protein Structure, Secondary | 1 | 2009 | 325 | 0.020 |
Why?
| | Protein Isoforms | 1 | 2009 | 338 | 0.020 |
Why?
| | Reed-Sternberg Cells | 1 | 2007 | 2 | 0.020 |
Why?
| | Recombinant Fusion Proteins | 1 | 2010 | 616 | 0.020 |
Why?
| | Adenoids | 1 | 2007 | 10 | 0.020 |
Why?
| | Palatine Tonsil | 1 | 2007 | 32 | 0.020 |
Why?
| | Protein Structure, Tertiary | 1 | 2009 | 796 | 0.020 |
Why?
| | Recombinant Proteins | 1 | 2009 | 1230 | 0.020 |
Why?
| | E2F2 Transcription Factor | 1 | 2005 | 15 | 0.020 |
Why?
| | Hydroxyurea | 1 | 2005 | 30 | 0.020 |
Why?
| | In Situ Hybridization, Fluorescence | 1 | 2007 | 309 | 0.020 |
Why?
| | E2F1 Transcription Factor | 1 | 2005 | 57 | 0.020 |
Why?
| | Precancerous Conditions | 1 | 2007 | 158 | 0.020 |
Why?
| | Immunocompromised Host | 1 | 2007 | 195 | 0.020 |
Why?
| | Biliary Atresia | 1 | 2007 | 185 | 0.010 |
Why?
| | Models, Molecular | 1 | 2009 | 1369 | 0.010 |
Why?
| | Lymph Nodes | 1 | 2007 | 419 | 0.010 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 1 | 2012 | 961 | 0.010 |
Why?
| | Risk Factors | 1 | 2017 | 8632 | 0.010 |
Why?
| | Polymerase Chain Reaction | 1 | 2007 | 993 | 0.010 |
Why?
| | Protein Binding | 1 | 2009 | 1890 | 0.010 |
Why?
| | RNA, Viral | 1 | 2007 | 565 | 0.010 |
Why?
| | Immunohistochemistry | 1 | 2007 | 1629 | 0.010 |
Why?
| | Molecular Sequence Data | 1 | 2005 | 2785 | 0.010 |
Why?
| | Biomarkers | 1 | 2010 | 3408 | 0.010 |
Why?
|
|
Porter's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|